iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.

Biotechnology

iECURE

Joseph Truitt

Brad Dickerson

Maryann A. Toto

Donna Lutz

Sue McGoldrick

Gabriel M. Cohn

David Garrett

Alex Monteith

Paul Firuta

Leadership Team

Regulatory and Quality Assurance Team

Clinical Operations Team

Teams at iECURE

Leadership Team

Regulatory and Quality Assurance Team

Clinical Operations Team